TGF-β signalling-related markers in cancer patients with bone metastasis

Authors:
  • MRMace L. Rothenberg
    Mace L. Rothenberg
  • TDThomas Daly
    Thomas Daly
  • ACAnn Cleverly
    Ann Cleverly
  • BBBrandi Berry
    Brandi Berry
  • SRSusanne K. Rhoades
    Susanne K. Rhoades
  • CRChad A. Ray
    Chad A. Ray
  • JFJeffrey Fill
    Jeffrey Fill
  • DFDaphne L. Farrington
    Daphne L. Farrington
  • LWLisa Anne Wallace
    Lisa Anne Wallace

Abstract
We measured transforming growth factor (TGF)-beta-dependent biomarkers in plasma and in peripheral blood mononuclear cells (PBMCs) to identify suitable pharmacodynamic markers for future clinical trials with TGF-beta inhibitors. Forty-nine patients with bone metastasis were enrolled in the study, including patients with breast (n=23) and prostate cancer (n=15). Plasma TGF-beta1 levels were elevated in more than half of the cancer patients (geometric mean 2.63 ng ml(-1)) and positively correlated with increased platelet factor 4 (PF4) levels, parathyroid-related protein (PTHrP), von Willebrand Factor (vWF) and interleukin (IL)-10. PBMC were stimulated ex vivo to determine the individual biological variability of an ex vivo assay measuring pSMAD expression. This assay performed sufficiently well to allow its future use in a clinical trial of a TGF-beta inhibitor.

This publication has 32 references indexed in Scilit: